FDA Approves Combination Treatment of Faslodex/Ibrance for Certain Metastatic Breast Cancers
News
The U.S. Food and Drug Administration (FDA) has approved expanding the use of AstraZeneca’s breast cancer drug Faslodex (fulvestrant), in combination with Pfizer’s Ibrance (palbociclib), to treat advanced breast cancers (BC). The combination ... Read more